Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Innoviva, Inc.'s quarterly P/E stands at 2.6x, down 85.7% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 27.4% YoY to 5.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 6.89 | 2.58 | 4.22 | 6.52 | — | 18.07 | 250.13 | — | 8.28 | 5.28 | 3.31 | 159.13 | 6.70 |
| — | -85.7% | -98.3% | — | — | +242.5% | +7448.2% | — | +23.7% | — | +219.7% | -56.9% | -72.3% | |
| P/S Ratio | 3.99 | 3.61 | 3.60 | 4.23 | 3.21 | 3.98 | 3.40 | 2.48 | 4.16 | 3.97 | 4.16 | 2.57 | 3.31 |
| — | -9.3% | +5.9% | +70.5% | -22.8% | +0.2% | -18.4% | -3.6% | +25.7% | +13.2% | +0.6% | -21.1% | -34.3% | |
| P/B Ratio | 1.64 | 1.45 | 1.54 | 2.37 | 1.76 | 2.11 | 1.82 | 1.54 | 1.83 | 2.02 | 1.78 | 1.50 | 1.80 |
| — | -31.2% | -15.6% | +54.0% | -4.0% | +4.6% | +1.9% | +2.6% | +1.8% | +23.8% | +2.8% | -39.8% | -45.2% | |
| P/FCF | 8.66 | 7.98 | 7.98 | 9.62 | 5.85 | 6.61 | 6.28 | 5.86 | 8.69 | 10.30 | 6.40 | 5.46 | 9.84 |
| — | +20.7% | +27.1% | +64.1% | -32.8% | -35.8% | -1.9% | +7.4% | -11.7% | -60.4% | -63.9% | +22.2% | +113.0% | |
| EV / EBITDA | 5.62 | 5.87 | 8.47 | — | — | 8.09 | 6.25 | 4.87 | 12.09 | 9.19 | 11.25 | 11.81 | 13.17 |
| — | -27.4% | +35.6% | — | — | -12.0% | -44.5% | -58.7% | -8.2% | +9.2% | -54.4% | -31.7% | +17.5% | |
| EV / EBIT | 7.00 | 7.40 | 3.43 | 5.66 | — | 13.65 | 27.77 | — | 7.65 | 6.03 | 19.34 | 9.72 | 10.99 |
| — | -45.8% | -87.6% | — | — | +126.4% | +43.6% | — | -30.4% | -24.6% | +28.6% | -43.8% | -1.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Innoviva, Inc.'s operating margin was 33.0% in Q4 2025, up 1.0 pp QoQ and down 14.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -7.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 30.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3% | 64.1% | 76.1% | 89.4% | 90.0% | 92.2% | 88.8% | 82.2% | 85.8% | 84.7% | 84.7% | 70.4% | 70.0% |
| — | -30.5% | -14.4% | +8.8% | +4.9% | +8.8% | +4.9% | +16.8% | +22.7% | +5.2% | +9.8% | -29.6% | -30.0% | |
| Operating Margin | 38.5% | 33.0% | 32.1% | -48.6% | -46.7% | 47.0% | 55.6% | 52.9% | 33.3% | 43.7% | 36.2% | 22.8% | 27.6% |
| — | -29.7% | -42.3% | -191.9% | -240.4% | +7.5% | +53.7% | +131.7% | +20.5% | -6.7% | +97.4% | -70.1% | -68.0% | |
| Net Margin | 63.8% | 139.1% | 83.4% | 63.5% | -52.6% | 22.1% | 1.4% | -33.6% | 47.1% | 71.7% | 122.0% | 1.6% | 45.7% |
| — | +527.9% | +6054.3% | +289.2% | -211.5% | -69.1% | -98.9% | -2223.5% | +3.3% | +169.0% | -69.1% | +82.1% | +160.7% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 29.1% | 15.0% | 10.4% | 9.4% | -7.0% | 3.0% | 0.2% | -5.1% | 5.3% | 9.4% | 13.9% | 0.2% | 6.2% |
| — | +402.9% | +5631.4% | +284.6% | -231.4% | -68.3% | -98.7% | -2309.6% | -14.3% | +183.5% | -68.5% | +36.5% | +111.4% | |
| ROA | 18.5% | 10.7% | 6.5% | 4.9% | -3.6% | 1.6% | 0.1% | -2.8% | 2.9% | 5.1% | 7.1% | 0.1% | 3.0% |
| — | +567.3% | +6487.9% | +276.8% | -225.3% | -68.3% | -98.6% | -2543.5% | -1.5% | +194.8% | -67.0% | +36.2% | +90.4% | |
| ROIC | 16.8% | 4.0% | 3.2% | -4.7% | -3.8% | 3.8% | 4.2% | 4.4% | 2.0% | 3.1% | 2.1% | 1.6% | 1.9% |
| — | +3.7% | -24.8% | -208.0% | -289.2% | +23.8% | +100.9% | +167.6% | +8.1% | +13.4% | +95.4% | -77.5% | -74.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 523.5% YoY to 14.64x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.32 | 0.63 | 0.70 | 0.65 | 0.67 | 0.68 | 0.64 | 0.67 | 0.72 | 0.81 | 0.80 |
| — | — | -52.5% | -6.9% | +9.2% | -1.9% | -5.7% | -16.1% | -20.0% | -30.8% | -15.6% | -15.9% | -18.8% | |
| Debt / EBITDA | — | — | 7.84 | — | — | 9.09 | 8.01 | 6.98 | 13.93 | 10.20 | 14.55 | 19.10 | 17.97 |
| — | — | -2.2% | — | — | -10.9% | -44.9% | -63.5% | -22.4% | -34.5% | -63.3% | -15.1% | +58.0% | |
| Current Ratio | 14.64 | 14.64 | 14.12 | 2.64 | 2.48 | 2.35 | 1.79 | 12.70 | 10.42 | 9.03 | 8.43 | 8.21 | 7.77 |
| — | +523.5% | +688.8% | -79.2% | -76.2% | -74.0% | -78.8% | +54.7% | +34.1% | +174.7% | +203.9% | +158.3% | +167.1% | |
| Quick Ratio | 13.85 | 13.85 | 13.33 | 2.44 | 2.30 | 2.21 | 1.64 | 11.40 | 9.17 | 7.96 | 7.31 | 7.02 | 6.47 |
| — | +528.1% | +714.2% | -78.6% | -74.9% | -72.3% | -77.6% | +62.4% | +41.7% | +177.1% | +212.1% | +123.1% | +122.4% | |
| Interest Coverage | 9.81 | 11.78 | 8.61 | -10.45 | -8.79 | 9.08 | 8.57 | 9.43 | 4.41 | 6.30 | 5.53 | 4.22 | 4.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonInnoviva, Inc.'s current P/E is 6.9x. The average P/E over the last 3 quarters is 4.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Innoviva, Inc.'s current operating margin is 38.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Innoviva, Inc.'s business trajectory between earnings reports.